MV BioTherapeutics SA

Spin-off from the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, aimed at shaping the intestinal microbiota for the cure and prevention of diseases such as bowel diseases and cancer. The gut ecosystem conditions the function of all our organs and plays a fundamental role in our wellbeing. The mucosal immune system has co-evolved with the intestinal microbiota to adapt its function to a number of environmental and possibly pathogenic factors. MV Bio leverages a microbiota-mediated mechanism regulating the physiological response of the intestinal immune system to amplify secretory IgA antibodies in dysbiotic conditions and in vaccination protocols. The lead indications of the patent protected ApyraMed® platform are treatments for Inflammatory Bowel Disease (IBD), enhancement of the tumoricidal response in cancer immunotherapy by selectively adapting the intestinal microbiota function to the activity of checkpoint inhibitors and the protection from antibiotic induced dysbiosis, thereby safeguarding our organism from opportunistic infections (e.g. by Clostridioides difficile and pathogenic Escherichia coli) that take advantage from the destruction of the intestinal resistance to colonization by enteropathogens.